Eli Lilly (LLY)
807.19
+0.00 (0.00%)
NYSE · Last Trade: Jun 11th, 8:16 AM EDT
If Hims were to align with Lilly, Citi warned, it would signal the company has "thrown in the towel" on compounded medications.
Via Stocktwits · June 11, 2025
Stay updated with the movements of the S&P500 index one hour before the close of the markets on Tuesday. Discover which stocks are leading as top gainers and losers in today's session.
Via Chartmill · June 10, 2025
The fast-food giant was cut from buy to sell over a potential double-digit loss in sales due to weight-loss drugs.
Via Investor's Business Daily · June 10, 2025
These companies own 97% of the weight loss drug market -- which could grow tenfold over the next decade -- and are developing next-generation offerings.
Via The Motley Fool · June 10, 2025
A sweeping overhaul of the CDC's top vaccine advisory panel is ripping through the medical world, while rattling pharma and biotech stocks.
Via Benzinga · June 10, 2025
The company said that the drug, MET-233i, demonstrated up to 8.4% mean placebo-subtracted weight loss at day 36.
Via Stocktwits · June 9, 2025
The company is planning to soon begin combination studies, testing two of its drugs in weight loss.
Via Investor's Business Daily · June 9, 2025
Chugai plans to pair its muscle-preserving drug with Eli Lilly's orforglipron, addressing muscle loss in obesity care as the market expands rapidly.
Via Benzinga · June 9, 2025
Via The Motley Fool · June 7, 2025
With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?
Via MarketBeat · June 7, 2025
Amgen is hoping to take on Eli Lilly and Novo Nordisk with a potential monthly shot, MariTide.
Via Investor's Business Daily · June 6, 2025

China's drug regulator accepted the companies’ NDA for a combination therapy targeting advanced renal cell carcinoma.
Via Stocktwits · June 4, 2025

Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38.
Via Benzinga · June 4, 2025

Camurus licensed its FluidCrystal drug delivery tech to Eli Lilly for global development of long-acting incretin therapies targeting metabolic diseases.
Via Benzinga · June 4, 2025

Dive deep into two popular dividend ETFs to determine which is right for your portfolio.
Via The Motley Fool · June 4, 2025